Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen

Trivedi, Premila; Hindmarsh, Peter C.; Ristell, Juha; Ristell, Leila; Mowat, Alex P.; Brook, C. G. D.

doi:10.1016/s0022-3476(89)80787-5

Cited by 63 publications

(41 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, these parameters can be expected to reflect the sensitivity of the skeleton to GH. The associations between most of these markers and HV at 12 months was similar to results reported by others (5,13,14,21,22). The best correlation with 1-year HV was found for urinary DPD at 4 weeks after the start of treatment.…”

Section: Discussionsupporting

confidence: 89%

A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency

Schönaü

Westermann²,

Rauch³

et al. 2001

European Journal of Endocrinology

105

View full text Add to dashboard Cite

Objective: To identify parameters which predict individual growth response to recombinant human GH (rhGH) therapy and to combine these parameters in a prediction model. Design: Fifty-eight prepubertal patients with GH deficiency (17 females) participated in this prospective multicenter trial with 1 year of follow-up. Methods: Auxological measurements, parameters of GH status and markers of bone metabolism were measured at baseline and at 1, 3 and 6 months after the start of rhGH treatment. Correlations with height velocity during the first 12 months of treatment HV 12 were calculated. Prediction models were derived by multiple regression analysis. Results: The model which best predicted HV 12 combined the following parameters: pretreatment bone age retardation as a fraction of chronological age, pretreatment serum levels of IGF-I, urinary levels of deoxypyridinoline (a marker of bone resorption) after 1 month of treatment and height velocity after 3 months of treatment. This model explained 89% of the variation in HV 12 with a standard deviation of the residuals of 0.93 cm/year. Defining successful rhGH therapy as a doubling of pretreatment height velocity, the model had a specificity of 90% and a sensitivity of 100% in predicting therapeutic success. Conclusions: This model is an accurate and practicable tool to predict growth response in GH-deficient children. It may help to optimize rhGH therapy by individual dose adjustment and contribute to improved overall outcomes.European Journal of Endocrinology 144 13±20

show abstract

Section: Discussionsupporting

confidence: 89%

A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency

Schönaü

Westermann²,

Rauch³

et al. 2001

European Journal of Endocrinology

105

View full text Add to dashboard Cite

show abstract

“…76 children with disorders of growth who had formed part of a cohort in a previous study (7) were assessed. Using diagnostic criteria previously described (7), 38 (3 1 male; 7 female) had growth hormone insufficiency, 2 1 (1 3 male; 8 female) had no endocrinologic abnormality but were of short stature (short normal), and 1 7 (5 male; 12 female) had tall stature; 14 of the tall subjects were pubertal.…”

Section: Methodsmentioning

confidence: 99%

“…During the synthesis of these collagens, large soluble propeptide domains are released into the circulation from the precursor procollagen molecules (4). A number of investigations have shown that serum concentrations of the aminopropeptide of type I11 procollagen, measured by RIA, reflect growth rates (5)(6)(7)(8)(9). Because growth hormone has well-established direct effects on bone growth but is without known direct effects on the growth of somatic tissue, it might be anticipated (10) that the serum concentration of PICP may be more useful in assessing growth than PIIINP, because type I collagen is found in both bone and somatic tissues, whereas type I11 collagen is only found in somatic tissues.…”

mentioning

confidence: 99%

Serum Concentrations of the Type I and III Procollagen Propeptides as Biochemical Markers of Growth Velocity in Healthy Infants and Children and in Children with Growth Disorders

et al. 1991

Self Cite

View full text Add to dashboard Cite

ABSTRACT. The reproducibility and specificity of a new, rapid, simple RIA for measuring the concentration of the soluble carboxypropeptide of type I procollagen (PICP) in serum was confirmed. Serum PICP was determined in 442 healthy Caucasian subjects ranging in age from 3 wk to 18 y. Highest PICP values (mean f SD: 2200 f 350 pg/L) occurred in infants less than 3 mo of age, falling by 70% at 2 y and by an additional 10% at 4 y. There was no significant change in serum PICP between 4 and 16 y of age (330 f 130 pg/L), but a decrease to adult levels of 4 6 0 pg/L occurred by 18 y. In 76 children with growth disorders, serum PICP was related to linear growth velocity (p < 0.001), although there were no significant differences in PICP among the 38 children with growth hormone insufficiency, the 21 short children with no endocrinologic abnormality, or the 17 tall children. All 15 prepubertal children treated with growth hormone for 3 mo showed significant increases in both growth velocity and serum PICP, with a significant relationship (p < 0.01) between the degree of increases. The rise in serum PICP at 3 mo (but not baseline PICP values) predicted the increase in growth velocity after 1 y of treatment. Similar changes were observed in the concentration of the aminopropeptide of type I11 procollagen, except that serum aminopropeptide of type I11 procollagen showed a definite increase during puberty and a wider spread of values in growth disorders. We conclude that measuring serum PICP by the new, reproducible assay reflects height velocity in prepubertal children and may be a useful biochemical means of monitoring growth rates. (Pediatr Res 30: 276-280, 1991) Abbreviations HV, height velocity PICP, carboxyterminal propeptide of type I procollagen PIIINP, aminoterminal propeptide of type I11 procollagenThe increased availability of biosynthetic human growth hor-

show abstract

“…To our knowledge, there have been no previous reports concerning bone and collagen turnover in children with Perthes'disease. P3NP, a marker of type III collagen synthesis in soft tissue, reflects overall somatic growth (Trivedi et al 1989). Its very low level at diagnosis, persisting throughout follow-up, is consistent with a widespread deficit in soft tissue collagen deposition accompanying the overall suboptimal growth in these children.…”

Section: Discussionmentioning

confidence: 84%

Children with acute Perthes' disease have asymmetrical lower leg growth and abnormal collagen turnover

Crofton¹,

Macfarlane²,

Wardhaugh³

et al. 2005

Acta Orthopaedica

View full text Add to dashboard Cite

Background Abnormalities in distal growth and low levels of insulin-like growth factor (IGF)-I have been reported in children with Perthes' disease. Our aim was to establish whether the acute phase of Perthes' disease is associated with abnormalities of growth, of bone or of collagen turnover.Methods We performed a cross-sectional study of 15 children (3-11 years of age, 13 boys) at acute presentation and a longitudinal cohort study of 9 children. We measured (1) the lengths of both lower legs (by knemometry) at weeks 1, 2, 6 and 12, (2) height and weight at presentation and at the second-year follow-up, and (3) levels of IGF-I, IGFBP-3, collagen markers and bone alkaline phosphatase at weeks 1 and 12, and in year 2.Results Height SD scores were normal at presentation but declined thereafter. Lower leg growth was not impaired at presentation but was asymmetrical, ceased during weeks 2-6, and then resumed symmetrically. Patients had persistently low IGF-I, low soft tissue collagen synthesis and enhanced collagen breakdown compared with age-and sex-related reference data. Markers of bone formation increased during follow-up.Interpretation Acute changes in lower leg growth reflected differential weight bearing, then immobilization and remobilization. Persistently low IGF-I may have contributed to low soft tissue collagen synthesis and growth. Changes in bone formation markers most likely reflected bone healing.

show abstract

Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen

Cited by 63 publications

References 12 publications

A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency

A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency

Serum Concentrations of the Type I and III Procollagen Propeptides as Biochemical Markers of Growth Velocity in Healthy Infants and Children and in Children with Growth Disorders

Children with acute Perthes' disease have asymmetrical lower leg growth and abnormal collagen turnover

Contact Info

Product

Resources

About